ImmunoReagents and Cell IDx Announce Corporate Alliance and New Product Launch

News Release,
ImmunoReagents and Cell IDx Announce Corporate Alliance and New Product Launch

RALEIGH, NC, USA – August 26, 2015 – Leading life science reagent manufacturer ImmunoReagents joins forces with Cell IDx, the industry’s leading manufacturer of UltraPolymer – HRP immunodiagnostic reagents.

“Cell IDx’s expertise in bioorganic chemistry and immunoassay development, coupled with ImmunoReagents’ high quality secondary and primary antibodies, provides us with the ability to offer high sensitivity HRP conjugates for the Immunohistochemistry and Chemiluminescence markets.” said Dr. Ann Black, president and founder of ImmunoReagents. “This strategic collaboration provides highly sensitive HRP polymer conjugates in vitro diagnostics for research and clinical applications”.

“Cell IDx is excited to be partnering with one of the industry leaders in the field of immunodetection” said Dr. David Schwartz, CEO and CSO of Cell IDx. “ImmunoReagents has a reputation for excellence and we are glad to add our high sensitivity secondary antibody HRP polymers to their expanding range of immunodetection reagents.”

About ImmunoReagents, Inc.

ImmunoReagents is a leading global manufacturer of quality antibodies and reagents used in research and in vitro diagnostics. Product offerings include a wide range of immunochemistry reagents such as purified immunoglobulins and primary antibodies, in addition to secondary antibodies covering a broad spectrum of immunoglobulins from various species. ImmunoReagents also provides custom manufacturing to meet specific customer requirements while adhering to cGMP guidelines and ISO quality systems requirements. The Company is located in Raleigh, North Carolina.

For more information, please see www.immunoreagents.com

About Cell IDx

Cell IDx was founded to be the technology leader in multiplexed cellular immunodiagnostics. We are a privately held biotechnology company committed to developing highly sensitive and specific reagents for research and clinical immunohistochemistry and other immunoassays. Underlying the recent success of next generation assays, the last piece of the puzzle has been the development of new tools and reagents that not only detect their targets with greater sensitivity and specificity but also satisfy the need to detect multiple targets simultaneously via multiplexing. The company is located in San Diego, California.

For more information, please see http://www.cellidx.com